Toxicological evaluation of PdTPPS 4 as a promising photosensitiser for antibacterial applications — An in vitro study
The rapid emergence of antimicrobial-resistant pathogens and the declining efficacy of conventional antibiotics have intensified the search for alternative therapeutic strategies. PdTPPS 4 (palladium(II) meso-tetra(4-sulphonatophenyl)porphyrin) is a novel water-soluble photosensitiser with promising photodynamic and antibacterial potential. In the current study, the dermatotoxicological profile of this compound was evaluated by using a number of mechanism-informed, validated non-animal methods. The in vitro assays undertaken in the current study were modified to achieve optimised conditions, but were based on the following Organisation for Economic Co-operation and Development (OECD) Test Guidelines: TG 439 ( in vitro skin irritation testing, with reconstructed human epidermis); and, for the evaluation of skin sensitisation potential, TG 442D (specifically, the ARE-Nrf2 luciferase test method (LuSens assay)) and TG 442C (the Direct Peptide Reactivity Assay (DPRA)). An immunoassay-based assessment of early inflammatory biomarkers (IL-1α, IL-18) was also performed, in order to detect potential sub-irritant responses. PdTPPS 4 showed no indication of skin irritation, inflammatory activation or sensitisation potential under the test conditions. These findings support the favourable dermal compatibility of PdTPPS 4 under non-irradiated (dark) conditions, and indicate low intrinsic dermatotoxicity in the tests performed. This study provides initial toxicological evidence supporting further investigation of PdTPPS 4 as a promising candidate photosensitiser, for use in future antimicrobial photodynamic therapy applications. These results not only demonstrate the dermatological safety of PdTPPS 4 , but also introduce a new methodological framework for the preclinical safety screening of photosensitisers by using exclusively non-animal OECD-guided assays. The current non-animal and mechanism-informed assessment of dermal toxicity contributes to both the ethical and translational advancement in the development of photodynamic therapeutic agents, supporting regulatory and clinical decision-making with regard to these compounds.
Authors
- Hana Bendová (ORCID: https://orcid.org/0000-0003-0374-3363)
- Hanna Dilenko (ORCID: https://orcid.org/0000-0002-8801-2094)
- Markéta Kolaříková (ORCID: https://orcid.org/0000-0002-4745-2667)
- Robert Bajgar (ORCID: https://orcid.org/0000-0003-4854-4114)
- Kristína Kejlová
- Marián Rucki (ORCID: https://orcid.org/0000-0001-6583-9964)
- Hana Kolářová (ORCID: https://orcid.org/0000-0002-6156-4841)
- Katerina Barton Tomankova (ORCID: https://orcid.org/0000-0002-3249-4522)
- Lada Svobodová (ORCID: https://orcid.org/0000-0002-4851-0507)
- Lucie Válková (ORCID: https://orcid.org/0000-0003-3854-1091)
Institutions
- Technical University of Liberec (CZ)
- Palacký University Olomouc (CZ)
Publication Details
- Journal
- Alternatives to Laboratory Animals
- Published
- 2026-11-21
- DOI
- https://doi.org/10.1177/02611929261506474
- Primary Topic
- Photodynamic Therapy Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00